Top 10 Stocks To Watch Right Now

The market appears to like the fact that Pfizer (PFE) won’t be able to buy AstraZeneca (AZN) at what could be an elevated price. AstraZeneca, not so much.

Reuters

Shares of AstraZeneca have dropped 11% to $71.19 at 2:28 p.m. today, while Pfizer has risen 1.1% to $29.43. Citigroup’s Andrew Baum and team say the selloff in AstraZeneca has created a buying opportunity:

Our in-depth November 2013 report laid out what we saw as the extreme undervaluation of AstraZeneca’s early/mid-stage oncology pipeline, >26% upside to consensus EPS post-2017 and the greatest valuation delta (>45% at that time) to our £49/share NPV estimate compared with its global peers. We updated our analysis…shortly ahead of PFE’s announced AZN bid. Following the -13% sell-off after today’s rejection by the AZN board of PFE’s £55/share offer, we add Buy-rated AstraZeneca to the Citi Focus List Europe based on our extensive previous analysis of its fundamental value drivers.

Top 10 Stocks To Watch Right Now: Fox Factory Holding Corp (FOXF)

Fox Factory Holding Corp incorporated on December 28, 2007, is a designer, manufacturer and marketer of suspension products used primarily on mountain bikes, side-by-side vehicles, or side-by-sides, on-road vehicles with off-road capabilities, off-road vehicles and trucks, all-terrain vehicles (ATVs), snowmobiles, specialty vehicles and applications, and motorcycles. The Company designs and markets its products to original equipment manufacturers (OEM’s) in its markets, and to consumers through the aftermarket channel.

The Company offers upper mid-end and high-end front fork and rear suspension products designed for cross-country, trail, all-mountain, free-ride and downhill riding in its mountain bike product category. It also offers ride-height adjustable seat post product. Its remote adjustable seat pos allows to adjust his or her seat position for uphill, rolling trail or downhill riding without having to stop the mountain bike to adjust the seat. Its mou ntain bike products are sold in three series: evolution series, performance series and factory series.

In its powered vehicle product category, the Company offers high-end suspension products for side-by-sides, on-road vehicles with off-road capabilities, off-road vehicles and trucks, ATVs, snowmobiles, specialty vehicles and applications, and motorcycles. Products for these vehicles are designed for trail riding, racing and performance. It products in the powered vehicle category range from two inch aluminum bolt-on shocks to its patented position sensitive internal bypass shocks. The Company sells its mountain bike suspension products to more than 150 domestic and international bike OEMs. It sells its suspension products for the powered vehicles industry to OEMs

Advisors’ Opinion:

  • [By Jon C. Ogg]

    Fox Factory Holding Corp. (NASDAQ: FOXF) saw its quiet period end: started as Outperform with a $23 price target at Baird, started as Overweight with a $21 price target at Piper Jaffray and started as Buy with a $23 price target at SunTrust. Shares are down about 0.5% at $18.05 as the implied upside is not that stellar for recent IPO coverage.

Top 10 Stocks To Watch Right Now: Denbury Resources Inc (DNR)

Denbury Resources Inc., incorporated in 1951, is an independent oil and natural gas company. As of December 31, 2011, the Company had 461.9 million barrel of oil equivalent of proved oil and natural gas reserves, of which 77% was oil. The Company’s oil and natural gas properties are concentrated in the Gulf Coast and Rocky Mountain regions in the United States. As of December 31, 2011, the Company’s properties with proved and producing reserves in the Gulf Coast region were situated in Mississippi, Texas, Louisiana and Alabama, and in the Rocky Mountain region were primarily situated in Montana, North Dakota, Utah and Wyoming. In April 2012, it sold certain non-operated assets in the Greater Aneth Field in the Paradox Basin of Utah to Resolute Energy Corporation and the Navajo Nation Oil and Gas Company. In December 2012, the Company closed its first phase of its previously announced Bakken sale and asset exchange with Exxon Mobil Corporation and its wholly owned subsidi ary XTO Energy Inc. In March 2013, it announced the closing of acquisition of producing property interests in the Cedar Creek Anticline (CCA) of Montana and North Dakota.

The Company’s CO2 source, Jackson Dome is located near Jackson, Mississipp. In addition to the proved reserves, it has an additional 2.5 trillion cubic feet of probable CO2 reserves at Jackson Dome. As of December 31, 2011, there have been 13 structures drilled within the Jackson Dome area and only one has not been productive. In addition to using CO2 for the Company’s Gulf Coast tertiary operations, it sells CO2 to third-party industrial users under long-term contracts and has three CO2 volumetric production payment contracts (VPPs). Approximately 91% of its average daily CO2 production during the year ended December 31, 2011 was used in its tertiary recovery operations on its own behalf and on behalf of other working interest owners in recovery fields, with the balance delivered to third -party industrial users. During 2011, the Company sold an av! erage of 89 million cubic feet per day of CO2 to commercial users, and the Company used an average of 920 million cubic feet per day for its tertiary activities.

In Eastern Mississippi properties, the Company has four tertiary operations (Soso, Martinville, Eucutta and Heidelberg Fields). The majority of the conventional oil production at Heidelberg is from waterflood units that produce from the Eutaw formation (at approximately 4,400 feet). The Company has converted all of the waterflood units in West Heidelberg to CO2 enhanced oil recovery (EOR). As of December 31, 2011, the Company either owned, or controlled through long-term financing leases, approximately 864 miles of CO2 pipelines in the Gulf Coast region. In addition to the NEJD CO2pipeline, the major pipelines are the Free State Pipeline (90 miles), the Delta Pipeline (110 miles) and the Green Pipeline (325 miles).

The Company’s primary Rocky Mountain CO2 source, Riley Ridge is located i n southwestern Wyoming. The gas composition from Riley Ridge is approximately 65% CO2, 19% natural gas, 5% hydrogen sulfide (H2S), 0.6% helium, and the remainder other gases. As of December 31, 2011, its interest in Riley Ridge and minor surrounding acreage contained net proved reserves of 415 billion cubic feet of natural gas and 2.2 trillion cubic feet of CO2 reserves. Bell Creek Field is located in southeast Montana. Cedar Creek Anticline (CCA) is primarily located in Montana. CCA is a series of 10 producing oil units. During 2011, the Company fracture stimulated 31 operated wells in the Bakken and four wells in the Selma Chalk utilizing water-based fluids.

Advisors’ Opinion:

  • [By Johanna Bennett]

    Denbury Resources (DNR) shares dropped 5.9% after oil-and-natural-gas explorer on Sunday announced that it will initiate quarterly dividend and raised its share repurchase plan to $250 million from the $109 million remaining in its program.

  • [By Claudia Assis]

    Denbury Resources Inc. (DNR)  declined 5.5%.

  • [By Matthew DiLallo]

    Planting trees is just the start. Another example of how Apache is lowering emissions is found at its Midale field in Saskatchewan, Canada. Apache is using carbon dioxide captured from a local coal-fired power plant and utilizing it to produce oil. The carbon dioxide is then sequestered in the field. It’s a process that’s increasingly being applied by fellow oil company Denbury Resources (NYSE: DNR  ) .

Top 10 Stocks To Watch Right Now: Celgene Corp (CELG)

Celgene Corporation is a global biopharmaceutical company primarily engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases. The Company is engaged in the research and development, which is designed to bring new therapies to market, and is engaged in research in several scientific areas that may deliver therapies, focusing areas, such as intracellular signaling pathways in cancer and immune cells, immunomodulation in cancer and autoimmune diseases, and therapeutic application of cell therapies. The Company’s primary commercial stage products include REVLIMID, VIDAZA, THALOMID, ABRAXANE and ISTODAX. Additional sources of revenue include a licensing agreement with Novartis, which entitles it to royalties on FOCALIN XR and the entire RITALIN family of drugs, the sale of services through its Cellular Therapeutics subsidiary and other miscellaneous licensing agreements. In March 2012, it acquir ed Avila Therapeutics.

The Company invests in research and development, and the drug candidates in its pipeline at various stages of preclinical and clinical development. These candidates include pomalidomide and apremilast, its oral anti-cancer and anti-inflammatory agents, PDA-001, its cellular therapy, oral azacitidine, CC-223 and CC-115 for hematological and solid tumor malignancies, CC-122, its anti-cancer pleiotropic pathway modifier, and ACE-011 and ACE-536 biological products for anemia in several clinical settings of unmet need. Celgene product candidates include Pomalidomide (CC-4047), Oral Anti-Inflammatory: Apremilast (CC-10004), CC-11050, Kinase Inhibitors:Tanzisertib (CC-930), Cellular Therapies: PDA-001, Activin Biology: Sotatercept (ACE-011) ACE-536, and Anti-tumor Agents: CC-22, CC-115, CC-122 and Oral Azacitidine. It owns and operates a manufacturing facility in Zofingen, Switzerland. The Company also owns and operates a drug product manufactur ing facility in Boudry, Switzerland.

Commercial! Stage Products

REVLIMID (lenalidomide) is an oral immunomodulatory drug marketed in the United States and many international markets, in combination with dexamethasone, for treatment of patients with multiple myeloma who have received at least one prior therapy. It is also marketed in the United States and certain international markets for the treatment of transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. REVLIMID is distributed in the United States through contracted pharmacies under the RevAssist program, which is a risk-management distribution program. Internationally, REVLIMID is distributed under mandatory risk-management distribution programs.

REVLIMID continues to be evaluated in numerous clinical trials worldwide either alone or in combination with one or more other therapies in the treatm ent of a range of hematological malignancies, including multiple myeloma (MDS) various lymphomas, chronic lymphocytic leukemia (CLL) other cancers and other diseases. VIDAZA (azacitidine for injection) is a pyrimidine nucleoside. VIDAZA is a Category 1 recommended treatment for patients with intermediate-2 and high-risk MDS and is marketed in the United States for the treatment of all subtypes of MDS. In Europe, VIDAZA is marketed for the treatment of intermediate-2 and high-risk MDS, as well as acute myeloid leukemia (AML) with 30% blasts and has been granted orphan drug designation for the treatment of MDS and AML.

THALOMID (thalidomide) is marketed for patients with newly diagnosed multiple myeloma and for the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL) an inflammatory complication of leprosy and as maintenance therapy for prevention and suppression of the cutaneous manifestation of ENL recurrence. THA LOMID is distributed in the United States under its System f! or Thalid! omide Education and Prescribing Safety (S.T.E.P.S.) program. Internationally, THALOMID is also distributed under mandatory risk-management distribution programs. ABRAXANE (paclitaxel albumin-bound particles for injectable suspension) is a solvent-free chemotherapy treatment option for metastatic breast cancer, which was developed using its nab technology platform. This protein-bound chemotherapy agent combines paclitaxel with albumin. As of December 31, 2011, ABRAXANE was in various stages of investigation for the treatment of expanded applications for metastatic breast; non-small cell lung; malignant melanoma; pancreatic; bladder and ovarian.

ISTODAX (romidepsin) has received orphan drug designation for the treatment of non-Hodgkin’s T-cell lymphomas, which includes CTCL and PTCL. The Company has licensed the worldwide rights (excluding Canada) regarding certain chirally pure forms of methylphenidate for FOCALIN and FOCALIN XR to Novartis. It also licensed to N ovartis the rights related to long-acting formulations of methylphenidate and dex-methylphenidate products which are used in FOCALIN XR and RITALIN LA.

Preclinical and Clinical-Stage Pipeline

The product candidates in the Company’s pipeline are at various stages of preclinical and clinical development. Pomalidomide is a small molecule that is orally available and modulates the immune system and other biologically important targets. Pomalidomide is being evaluated in a phase III clinical trial for the treatment of myelofibrosis and a phase III clinical trial evaluating pomalidomide as a treatment for patients with relapsed/refractory multiple myeloma is accruing patients.

The Company is developing a product, ORAL ANTI-INFLAMMATORY AGENTS, which is orally available small molecules that target PDE4, an intracellular enzyme that modulates the production of multiple pro-inflammatory and anti-inflammatory mediators, including interleukin-2 (IL-2), IL-10, IL-12, IL-23, INF-gamma, TNF-a, leukotrienes,! and nitr! ic oxide synthase. Its investigational drug, apremilast (CC-10004), is used for the treatment of moderate to severe psoriasis and active psoriatic arthritis and is being evaluated in a phase II trial for rheumatoid arthritis and six phase III multi-center international clinical trials. In addition, it is investigating its oral PDE4 inhibitor, CC-11050, which is an anti-inflammatory compound that treat a variety of chronic inflammatory conditions, such as Cutaneous Lupus Erythematosus (CLE).

The Company’s oral kinase inhibitor platform includes inhibitors of the c-Jun N-terminal kinase (JNK) mTOR kinase, spleen tyrosine kinase (Syk) c-fms tyrosine kinase (c-FMS) and DNA-dependent protein kinase (DNAPK). Its oral Syk, c-FMS and DNAPK kinase inhibitors are being investigated in pre-clinical studies. The Company’s new second generation JNK inhibitor, tanzisertib (CC-930), is being evaluated in a phase II trial for the treatment of idiopathic pulmonary fibrosis a nd a phase II trial for the treatment of discoid lupus is accruing patients. Amrubicin is a third-generation fully synthetic anthracycline molecule with potent topoisomerase II inhibition.

At Celgene Cellular Therapeutics (CCT), it is researching stem cells derived from the human placenta, as well as from the umbilical cord. CCT is the Company’s research and development division. Stem cell based therapies provide disease-modifying outcomes for serious diseases, which lack adequate therapy. It has developed technology for collecting, processing and storing placental stem cells with broad therapeutic applications in cancer, auto-immune diseases, including Crohn’s disease, multiple sclerosis, neurological disorders, including stroke and amyotrophic lateral sclerosis (ALS), graft-versus-host disease, and other immunological / anti-inflammatory, rheumatologic and bone disorders.

The Company has collaborated with Acceleron Pharma, Inc. (Acceleron) to de velop sotatercept. Two phase I clinical studies have been co! mpleted. ! An additional phase II clinical study has been initiated and is ongoing related to treatments for end-stage renal anemia and to evaluate effects on red blood cell mass and plasma volume.

The Company competes with Abbott Laboratories, Amgen Inc. (Amgen), AstraZeneca PLC., Biogen Idec Inc., Bristol-Myers Squibb Co., Eisai Co., Ltd., F. Hoffmann-LaRoche Ltd., Johnson and Johnson, Merck and Co., Inc., Novartis AG, Pfizer, Sanofi and Takeda Pharmaceutical Co. Ltd. (Takeda).

Advisors’ Opinion:

  • [By Ben Levisohn]

    Celgene (CELG) was on the receiving end of an upgrade today, but the upside has been limited as the biotech sector continues to sell off.

    Shares of Celgene gained 0.6% to $142.06 today, even as Amgen (AMGN) dropped 2% to 111.41, Biogen (BIIB) fell 3.1% to $285.81 and the SPDR S&P Biotech ETF (XBI) declined 3.9% to $124.37, extending its losing streak to three days. Gilead Sciences (GILD) dipped 0.2% to $73.90, ending a nine-day winning streak

    In a report titled “It’s Time…We Think,” Piper Jaffray’s Joshua Schimmer and team explain why they raised their rating on Celgene:

    The biotech sector has cooled off significantly over the past couple of months. Even a crushing EPS beat by [Gilead] barely moved that stock. Growth in general has come under pressure, and we are cognizant that high-multiple stocks may struggle to perform. While [Celgene] can’t yet be considered a “value” stock trading at a 2014 P/E multiple of 20x, it’s 20%+ sustainable EPS CAGR means it will eventually either become a value stock or see multiple stabilization with share performance driven by organic EPS growth…

    We believe the valuation now reflects a conservative 2024 Revlimid patent expiry and excludes meaningful contribution from the advancing pipeline. As such, we are less concerned with Revlimid’s May 15 Markman hearing outcome for the Revlimid polymorph patents since we believe a settlement somewhere between the method of use (2024) and polymorph (2027) dates is the most likely outcome regardless. Such a settlement could come this year and act as a potent catalyst to lift shares out of their doldrums.  [Celgene] is attuned to delivering shareholder value and we believe will fight aggressively to lift the Revlimid polymorph patent overhang and deliver sustainable EPS growth. We are upgrading from Neutral to OW…

    At least the market noticed, even if the gain wasn’t much.<

  • [By Todd Campbell]

    Biotech stocks have taken a punishing nose-dive over the past month as investors step aside following significant gains. However, the current share slide is likely more a result of emotion than any long-term changes at drug developer heavyweights Celgene (NASDAQ: CELG  ) , AbbVie (NYSE: ABBV  ) , and Gilead (NASDAQ: GILD  ) .

  • [By Ben Levisohn]

    Maybe, notes RBC Capital Markets’ Michael Yee and John Chung, who look at the free-cash-flow yield for Gilead Sciences (GILD) and Celgene (CELG).

Top 10 Stocks To Watch Right Now: Highpower International Inc (HPJ)

Highpower International, Inc., incorporated on January 3, 2006, is engaged in the production and sales of rechargeable nickel-metal hydride (Ni-MH) batteries, lithium batteries and battery systems. The Company also recycles scrap battery materials through outsourcing and resells the recycled materials to some of its customers. The Company’s wholly owned subsidiary is Hong Kong Highpower Technology Company Limited (HKHTC). HKHTC’s wholly owned subsidiaries Shenzhen Highpower Technology Company Limited (SZ Highpower), Highpower Energy Technology (Hui Zhou) Company Limited (HZ Highpower), Springpower Technology (Shenzhen) Company Limited (SZ Springpower) and Icon Energy System Company Limited (ICON) and SZ Highpower’s wholly owned subsidiary Ganzhou Highpower Technology Company Limited (Ganzhou Highpower).

The Company’s Ni-MH rechargeable batteries are solutions for many applications. The Company’s Ni-MH rechargeable batteries offer capacity and energy density. As a result, users can expect a longer time between charges and longer running time. The Company’s Ni-MH rechargeable batteries are available in both cylindrical and prismatic shapes. The Company produces Li-ion batteries and Li-polymer batteries with hundreds of different models and specifications. As of December 31 2011, the Company produced an average of 1,520,000 lithium battery units per month.

The Company’s batteries fall into two main categories, such as consumer batteries and industrial batteries. The Company’s consumer batteries category produces Ni-MH and lithium batteries, which offers power capacity, allowing for longer working time and shortened charging time during equivalent working periods. The Company produces A, AA and AAA sized batteries in blister packing, as well as chargers and battery packs. The Company’s industrial batteries are designed for electric bikes, power tools and electric toys. They are specifically designed f or high-drain discharge applications.

The Comp! any competes with SANYO Electric Co., Ltd., Panasonic, BYD Company Ltd., GPI International, Ltd., GS Yuasa Corporation, Desay Corp., Coslight Group, Tianjin Lishen Battery Co. Ltd. and ATL.

Advisors’ Opinion:

  • [By Kyle Woodley]

    The short, sucky answer? A lot:

    Plans for a “Gigafactory” meant to produce millions of electric-car batteries ginned up excitement, but also raised eyebrows. The Wall Street Journal reported on skepticism in the space — including from heads at Volkswagen (VLKAY) and battery maker Highpower International (HPJ). Now, even planned investment partner Panasonic (PC) now sounds iffy on the project, with company Kazuhiro Tsuga saying “the investment risk is definitely larger.” Not good. There also was Tesla’s direct sales snafu. New Jersey Gov. Chris Christie huffed and puffed and (on March 11) successfully blew down Tesla’s direct sales model, with the Motor Vehicle Commission approving a measure to enforce an already-existing ban on direct sales. On the flip side, Tesla has scored victories in New York and Ohio in the past month, and is making progress in Arizona (which has a little incentive on the board). Production of the Model X has been pushed further back, to 2015. Musk’s reasons — mostly having to do with focusing on bolstering Model S sales — are valid, but that doesn’t really soften the blow of a longer wait for the much-anticipated addition to Tesla’s line. To address the issue of battery fires in the Model S, TSLA added titanium shields and aluminum deflector plates to new vehicles and offered to install them for free in all its existing cars. Tesla’s margins are excellent, and there’s no hard number on the cost impact of the fix, but titanium ain’t cheap. This definitely isn’t going to add to Tesla’s bottom line. What Now?

    I won’t belabor you with my bullish position on TSLA stock, but if you want, you can see it here. In short, Musk is a genius; Tesla products are quality and appeal to (and are priced for) the all-important luxury segment; and just given size and scale, TSLA has oh-so-much room to grow.

Top 10 Stocks To Watch Right Now: Amazonica Corp (AMZZ)

Amazonica, Corp., incorporated on February 6, 2010, is a development-stage company. The Company is engaged in the field of marketing and distributing hardwood flooring and other construction materials.

The Company is a distributor of Brazilian hardwood flooring. Brazilian hardwood is manufactured from rare types of wood, such as Rose Wood, Snake Wood, Brazilian Teak, Santos Mahogany, Tigerwood, Brazilian Walnut and others. As of August 13, 2013, the Company had no revenues.

Advisors’ Opinion:

  • [By Peter Graham]

    Small cap stocks Banjo & Matilda, Inc (OTCMKTS: BANJ), Amazonica Corp (OTCBB: AMZZ) and Guardian 8 Holdings (OTCMKTS: GRDH) have been getting some extra attention in various investment newsletters or email alerts. Of course, there is nothing wrong with properly disclosed promotion or investor relations type of activities but they can cause problems for unwary investors and traders alike. So how hot are these three small cap stocks? Here is a closer look and a reality check:

Top 10 Stocks To Watch Right Now: Pool Corporation (POOL)

Pool Corporation operates as a wholesale distributor of swimming pool supplies, equipment, and related leisure products in North America and Europe. The company offers approximately 100,000 national brand and Pool Corporation branded products. It sells maintenance products, such as chemicals, supplies, and pool accessories; repair and replacement parts for cleaners, filters, heaters, pumps, and lights; packaged pool kits, including walls, liners, braces, and coping for in-ground and above-ground pools; pool equipment and components for new pool construction and the remodeling of existing pools; and irrigation and landscape products, such as professional lawn care equipment. The company also offers complementary products, including building materials used for pool installations and remodeling, such as concrete, plumbing and electrical components, and pool surface and decking materials; and other discretionary recreational and related outdoor lifestyle products. Pool Corpora tion serves swimming pool remodelers and builders, retail swimming pool stores, swimming pool repair and service businesses, landscape construction and maintenance contractors, and golf courses. The company was founded in 1993 and is based in Covington, Louisiana.

Advisors’ Opinion:

  • [By Seth Jayson]

    When judging a company’s prospects, how quickly it turns cash outflows into cash inflows can be just as important as how much profit it’s booking in the accounting fantasy world we call “earnings.” This is one of the first metrics I check when I’m hunting for the market’s best stocks. Today, we’ll see how it applies to Pool (Nasdaq: POOL  ) .

Top 10 Stocks To Watch Right Now: Questar Corporation(STR)

Questar Corporation operates as an integrated natural gas holding company. The company develops and produces natural gas and crude oil from its properties located in the Rocky Mountain region, primarily in the Pinedale, Moxa Arch, Vermillion, and Uinta producing areas. It also provides interstate natural gas-transportation and underground-storage services in Utah, Wyoming, and Colorado; and wellhead automation and measurement services for Rockies oil and gas producers. The company owns and operates approximately 2,568 miles of interstate pipeline with total firm-capacity commitments of 4,983 Mdth per day transporting natural gas from Rocky Mountain producing areas to other pipeline systems, distribution systems, and other utility systems; the Overthrust Pipeline in southwestern Wyoming and the eastern segment of Southern Trails Pipeline, a 487-mile line that extends from the Blanco hub in the San Juan Basin to just inside the California state line near the Arizona border; the White River Hub facilities that connect with 6 interstate-pipeline systems and a processing plant near Meeker, Colorado; the Clay Basin storage facility, an underground-storage reservoir in the Rocky Mountain region; and gathering lines and processing facilities, which provide gas-processing services for third parties near Price, Utah. In addition, it distributes natural gas as a public utility in Utah, southwestern Wyoming, and a small portion of southeastern Idaho. Questar Corporation was founded in 1922 and is headquartered in Salt Lake City, Utah.

Advisors’ Opinion:

  • [By Jason Hall]

    If you think natural gas prices could wreak havoc on companies like Clean Energy Fuels  (NASDAQ: CLNE  )  and Questar’s  (NYSE: STR  ) refueling division, you probably don’t understand how it all adds up “at the pump.”

  • [By Jonas Elmerraji]

    We’re seeing the exact same price setup in shares of mid-cap natural gas company Questar (STR), even if the chart looks a little different at first glance. Like REGN, Questar is currently forming a downtrending channel, but in this case, the channel is bounded to the downside by two extra support levels. Don’t expect support to provide a reprieve from selling, though – the trend is clearly down from here.

    STR is sitting up near trendline resistance right now, which provides an optimal time to exit a position in shares. This stock has gotten swatted down on each of the last three attempts to push through the top of the channel, and with shares slipping for a fourth time, the message is pretty clear that the trendline isn’t going to break this time around either.

    Enstar is currently forming a descending triangle pattern, a bearish price setup that’s formed by a horizontal resistance level below shares and downtrending support pressing to the upside. Basically, as shares of ESGR bounce in between those two technical price levels, they’re getting squeezed closer and closer to a breakdown below support at $133. A move through that $133 price level is the signal to sell (or short) this name.

    Relative strength is showing no signs of improvement in ESGR right now, which means that even after shedding almost 10% from its highs, this stock is still failing to keep up with the S&P’s performance. Keep a close eye on this name while shares remain within reach of $133.

  • [By Eric Volkman]

    Questar (NYSE: STR  ) is opening its financial taps a little wider to return money to shareholders. The company has declared a dividend of $0.18 per share of its common stock, to be paid on June 10 to shareholders of record as of May 24. That amount is $0.01, or 6%, higher than the company’s previous payout of $0.17. This was distributed in March.

Top 10 Stocks To Watch Right Now: Qihoo 360 Technology Co. Ltd.(QIHU)

Qihoo 360 Technology Co. Ltd. provides Internet and mobile security products in the People’s Republic of China. Its principal products include 360 Safe Guard, an Internet security product for Internet security and system optimization; 360 Anti-Virus, an anti-virus application to protect users? computers against trojan horses, viruses, worms, adware, and other forms of malware; and 360 Mobile Safe, a security program for the Google Android, Apple iOS, and Nokia Symbian smartphone operating systems. The company?s platform products comprise 360 Safe Browser, a Web browser; 360 Personal Start-up Page, a default homepage of 360 Safe Browser and a key access point to popular and preferred information and applications; 360 Application Store, a key access point to securely obtain and manage software and applications; and 360 Safebox, a solution that protects users against thefts of personal account information. It also provides online advertising services, including online marketi ng services and search referral services; and Internet value-added services comprising the operation of Web games developed by third-parties, remote technical support, and cloud-based services. The company was formerly known as Qihoo Technology Company Limited and changed its name to Qihoo 360 Technology Co. Ltd. in December 2010. Qihoo 360 Technology Co. was founded in 2005 and is based in Beijing, the People?s Republic of China.

Advisors’ Opinion:

  • [By Adam Levy]

    Chinese Internet stocks have taken a beating over the last couple months. Shares of Baidu (NASDAQ: BIDU  ) and Qihoo 360 (NYSE: QIHU  ) have fallen about 14% and 30% from their 52-week highs, respectively. At these prices, both stocks appear attractive.

  • [By Kevin Cook , Zacks Investment Research]

    The Chinese have made it clear they like to build their own dominant companies in key industries, like the Internet for instance. For this reason, hedge fund manager John Burbank of Passport Capital has major investments in Baidu (BIDU), Qihoo 360 (QIHU), which specializes in Internet security, search, and mobile apps, and SouFun (SFUN) which he calls the “Zillow of China.”

  • [By Louis Navellier]

    Qihoo 360 Technology Co. Ltd (QIHU)  is a stock I have mentioned a few times in the past few weeks. The company provides Internet and mobile security products in the People’s Republic of China and is growing a very high rate. In the most recent quarter this company had sales growth of over 100% and earnings surged by more than 200% year over year. They are now the undisputed leader in smart phone security in China with over 70% market share.

Top 10 Stocks To Watch Right Now: BioCryst Pharmaceuticals Inc.(BCRX)

BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops small-molecule pharmaceuticals that block key enzymes involved in infectious diseases, cancer, and inflammatory diseases. It uses structure-based drug design, which incorporates multiple scientific disciplines, including biology, crystallography, medicinal chemistry, and computer to develop new therapeutic candidates. The company has three novel late-stage compounds in development, which include Peramivir, a neuraminidase inhibitor for the potential treatment of influenza; BCX4208, a purine nucleoside phosphorylase (PNP) inhibitor for gout; and Forodesine, a PNP inhibitor for cutaneous T-cell lymphoma (CTCL) and chronic lymphocytic leukemia (CLL). Peramivir is being developed under a contract from the Biomedical Advanced Research and Development Authority within the United States Department of Health and Human Services. Forodesine has been granted orphan drug status by the FDA for thr ee indications, which include T-cell non-Hodgkin?s lymphoma, including CTCL; CLL and related leukemias, including T-cell prolymphocytic leukemia, adult T-cell leukemia, and hairy cell leukemia; and for treatment of B-ALL. The FDA has also granted fast track status to the development of forodesine for the treatment of relapsed or refractory T-cell leukemia, and special protocol assessment from the FDA for forodesine to conduct a pivotal clinical trial in CTCL with an oral formulation. The company announced the initiation of a Phase 2b study of BCX4208 as add-on therapy in gout patients who have not responded to allopurinol therapy alone. BioCryst Pharmaceuticals utilizes crystallography and structure-based drug design to discover additional compounds and to progress others through pre-clinical and early development to address the unmet medical needs of patients and physicians. The company was founded in 1986 and is headquartered in Durham, North Carolina.

Advisors’ Opinion:

  • [By GuruFocus]

    George Soros (Trades, Portfolio) just reported his first quarter portfolio. He buys Citrix Systems Inc, Baker Hughes Inc, Comcast Corp, Spansion Inc, etc during the 3-months ended 03/31/2014, according to the most recent filings of his investment company, Soros Fund Management LLC. As of 03/31/2014, Soros Fund Management LLC owns 305 stocks with a total value of $10.1 billion. These are the details of the buys and sells.New Purchases: BHI, CODE, CTRP, CLI, AVB, COMM, CNQ, AGO, AUY, ATML, ASH, BXMT, CSTM, AEM, CMA, ARE, CHKP, AUQ, BEAV, CX, ADSK, AALCP, BLK, AIG, BIIB, ADEP, AMRI, ARWR, ATHX, BALT, BCRX, BEAT, CFX, CLFD, CUR, CODE,Added Positions: CTXS, CMCSA, CNP, ALTR, BRCD, CBS, CRM, CHTR, CCJ, CIEN, BIDU, ALLE, ABT, CDNS, ACT,Reduced Positions: AAPL, CCI, AMT, ABBV, AAL, BITA, AL, ANGI, ARIA, CBST, BA, BIRT, EXAR,Sold Out: C, BAC, CRI, AMZN, AGN, CF, BRCM, COTY, BMY, AMCX, CAR, A, ADBE, AFL,For the details of George Soros (Trades, Portfolio)’s stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=George+SorosThis is the sector weightings of his portfolio:Technology18.9%Energy14%Healthcare8.3%Consumer Defensive8.2%Communication Services8.1%Consumer Cyclical5.4%Industrials5.1%Basic Materials4.9%Financial Services2.5%Real Estate1.9%Utilities0.5%These are the top 5 holdings of George Soros (Trades, Portfolio)1. Teva Pharmaceutical Industries Ltd (TEVA) – 10,310,041 shares, 5.4% of the total portfolio. Shares added by 10.67%2. Herbalife Ltd (HLF) – 4,901,337 shares, 2.8% of the total portfolio. Shares added by 52.9%3. EQT Corp (EQT) – 2,573,814 shares, 2.5% of the total portfolio. Shares added by 3.27%4. Adecoagro SA (AGRO) – 25,915,076 shares, 2.1% of the total portfolio.5. Halliburton Co (HAL) – 3,596,353 shares, 2.1% of the total portfolio. Shares reduced by 20.73%New Purchase: Baker Hughes Inc (BHI)George Soros (Trades, Portfolio) initiated holdings in Baker Hughes Inc. His purchase prices were between $51.82 and $65.2 7, with an estimated

  • [By John Udovich]

    While the Twitter IPO has been grabing everyone’s attention, biotech IPOs continue to dominate both biotech and IPO news with Karyopharm Therapeutics Inc (NASDAQ: KPTI) going public yesterday and Relypsa (NASDAQ: RLYP), TetraLogic Pharmaceuticals (NASDAQ: TLOG), Vital Therapies (NASDAQ: VTL) and Xencor (NASDAQ: XNCR) filing to go public in the near future (despite the sector producing some ugly charts for the month of October) plus another small cap called TNI BioTech (OTCMKTS: TNIB) has also been producing a steady flow of news:

    Karyopharm Therapeutics Debuts. Yesterday, small cap Karyopharm Therapeutics, which is working on a drug that aids the body’s natural tumor-suppressing proteins, debuted at the top of its range to raise $109 million in an upsized offering of 6.8 million shares at $16 apiece with shares closing at $16.81. It should be noted that Karyopharm Therapeutics’ lead drug candidate (Selinexor) is in early-stage clinical trials and the company lost lost nearly $12.5 million on revenue of $366,000 during the first six months of this year. Biotech IPOs by Region. On an interesting note, Luke Timmerman, the National Biotech Editor of Xconomy, has written a good article tracking biotech or life sciences IPOs by region. By his count, Boston is home to eight of the 45 (18%) of the life sciences IPOs this year (its companies have also raised the most money – about $770 million) plus the New York/northern New Jersey region is also home to eight. San Diego came in third with six IPOs followed by San Francisco with five while only five of the 45 biotech IPOs came from outside the US (Three from Israel and two from Europe). However, the above figures may change as by his account, there are 15 additional biotech companies in line to go public. More Biotechs Set IPO Terms. The small cap biotech space is about to be joined by a few new additions as a couple of biotechs file to go public over the past week or so: Relypsa, which is d

  • [By Roberto Pedone]

    Another under-$10 name in the bio therapeutic space that’s starting to move within range of triggering a major breakout trade is BioCryst Pharmaceuticals (BCRX), which designs, optimizes and develops novel drugs that block key enzymes involved in cancer, viral infections and autoimmune diseases. This stock has been on fire so far in 2013, with shares up a whopping 380%.

    If you take a look at the chart for BioCryst Pharmaceuticals, you’ll notice that this stock recently formed a double bottom chart pattern at $6.07 to $6.24 a share. Following that bottom, shares of BCRX are now starting to spike higher right off its 50-day moving average of $6.50 a share. That spike is quickly pushing shares of BCRX within range of triggering a major breakout trade.

    Market players should now look for long-biased trades in BCRX if it manages to break out above some near-term overhead resistance levels at $6.88 to $6.89 a share, and then once it takes out more resistance at $7.56 to its 52-week high at $7.80 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 2.51 million shares. If that breakout triggers soon, then BCRX will set up to enter new 52-week-high territory above $7.80, which is bullish technical price action. Some possible upside targets off that breakout are $10 to $12 a share.

    Traders can look to buy BCRX off weakness to anticipate that breakout and simply use a stop that sits right below those key near-term support levels at $6.24 to $6.07 a share. One can also buy BCRX off strength once it clears those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.

  • [By Sean Williams]

    Perhaps no shareholders jumped for more joy over the past week than those of BioCryst Pharmaceuticals (NASDAQ: BCRX  ) , whose shares shot up 88% this week on word of a positive early-stage clinical trial for BCX4161. In a different context, shares have now jumped 155% in just the past two weeks. The oral experimental drug, BCX4161, which is designed to treat a rare condition known as hereditary angioedema (HAE), was considered safe and well tolerated among patients, and the company anticipates moving on to mid-stage testing soon. However, as the Fools Brian Orelli was quick to point out, this data came from a subset of healthy volunteers, and there’s little guarantee it will translate into success in future trials on patients that do suffer from HAE.

Top 10 Stocks To Watch Right Now: United Therapeutics Corporation(UTHR)

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of therapeutic products for patients with chronic and life-threatening diseases in the United States and internationally. It offers Remodulin, Tyvaso, and Adcirca for the treatment of pulmonary arterial hypertension (PAH). The company also develops Oral Treprostinil (UT-15C), a new drug application filed with the United States Food and Drug Administration for the treatment of PAH. Its development products under Phase III clinical trials include Oral Treprostinil (UT-15C) Combination Therapy for PAH; Ch14.18 monoclonal antibody (MAb) targeting Neuroblastoma; and Remodulin for the treatment of PAH in the United States, the United Kingdom, France, Germany, Italy, and Japan. The company?s development products under Phase I clinical trials comprise Beraprost-MR for PAH in North America, Europe, Mexico, South America, Egypt, India, South Africa, and Australia; 8H9 MAb targ eting Metastatic brain cancer; and IW001 for the treatment of Idiopathic pulmonary fibrosis and primary graft dysfunction. Its pre-clinical stage products consist of Glycobiology Antiviral Agents for viral infectious diseases; PLacental eXpanded cells targeting PAH; and pulmonary tissue replacement and remodeling products for the treatment of end-stage lung disease. The company serves pharmaceutical wholesalers through specialty pharmaceutical distributors and other distributors. United Therapeutics Corporation was founded in 1996 and is headquartered in Silver Spring, Maryland.

Advisors’ Opinion:

  • [By John Udovich]

    The biotech sector may have lost some favor on Wall Street, but there is still plenty of interesting or overlooked news about the sector and/or biotech stocks like InterMune Inc (NASDAQ: ITMN), Biogen Idec Inc (NASDAQ: BIIB), Alexion Pharmaceuticals, Inc (NASDAQ: ALXN), United Therapeutics Corporation (NASDAQ: UTHR) and TNI BioTech, Inc (OTCMKTS: TNIB):

  • [By George Budwell]

    United Therapeutics (NASDAQ: UTHR  ) soared over 30% last week after receiving approval from the Food and Drug Administration for its extended-release oral tablets for pulmonary arterial hypertension, or PAH, known as Orenitram. This approval marks the company’s fifth with the FDA for PAH, which is currently the company’s primary revenue generator. Looking ahead, this approval should help to grow United Therapeutics revenue by 5% to 10% next year.